肌生成抑制素在2型糖尿病合并动脉粥样硬化中的研究进展

doi:10.3969/j.issn.1003-9198.2022.02.024

[1] JOSHUA T B, IRFAN M A, MERRY W M, et al. Effect of myostatin deletion on cardiac and microvascular function[J]. Physiol Rep, 2017, 5(23):13525.
[2] MCPHERRON A C, LAWLER A M, LEE S J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member[J]. Nature, 1997, 387(6628):83-90.
[3] SRIRAM S, SUBRAMANIAN S, SATHIAKUMAR D, et al. Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-κB[J]. Aging Cell, 2011, 10(6):931-948.
[4] CLAUS B, NIELSEN A R, FISCHER C P, et al.Plasma and muscle myostatin in relation to type 2 diabetes[J]. PLoS One, 2012, 7(5):37263.
[5] ESTRELLAS K M, CHUNG L, CHEU L A, et al. Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy[J]. J Biol Chem, 2018, 293(40):15594-15605.
[6] TU P, BHASIN S, HRUZ P W, et al. Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in ldlr null mice[J]. Diabetes, 2009, 58(8):1739-1748.
[7] 杨瑾, 周播江. 肌肉生长抑制素基因的研究进展[J]. 遵义医学院学报, 2018, 41(4):513-518.
[8] EVELINE A C, MARGREET R, WOUTER J J, et al. Myostatin inhibits vascular smooth muscle cell proliferation and local 14q32 microrna expression, but not systemic inflammation or restenosis[J]. Int J Mol Sci, 2020, 21(10):3508.
[9] LEE S, LEHAR A, LIU Y, et al. Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A[J]. Proc Natl Acad Sci U S A, 2020, 117(49):30907-30917.
[10] DELANAYE P, BATAILLE S, QUINONEZ K, et al. Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis[J]. J Renal Nutr, 2019, 29(6):511-520.
[11] CAMPOREZ J G, PETERSEN M C, ABUDUKADIER A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice[J]. Proc Natl Acad Sci U S A, 2016, 113(8):2212-2217.
[12] CAMPOREZ J, PETERSEN M C, ABUDUKADIER A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice[J]. Proc Natl Acad Sci, 2016, 113(8):2212-2217.
[13] WILKES J J, LLOYD D J, GEKAKIS N. Loss-of-function mutation in myostatin reduces tumor necrosis factor[alpha] production and protects liver against obesity-induced insulin resistance[J]. Diabetes, 2009, 58(5):1133-1143.
[14] LAWRENCE T B, ISAAC G, SIMON M, et al. Myostatin is elevated in congenital heart disease and after mechanical unloading[J]. PLoS One, 2011,6(9):23818.
[15] LEBRASSEUR N K. Building muscle, browning fat and preventing obesity by inhibiting myostatin[J]. Diabetologia, 2012, 55(1):13-17.
[16] LIU X, PAN J P, BAUMAN W A, et al. AdipoRon prevents myostatin-induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line[J]. Physiol Rep, 2019, 7(13):14152.
[17] ANTONY N, BASS J J, MCMAHON C D, et al. Myostatin regulates glucose uptake in BeWo cells[J]. Physiol Endocrinol Metab, 2007, 293(5):1296-1302.
[18] SIMONE C, NICHOLE N, ANDREI M C, et al. Mechanisms of muscle insulin resistance and the cross-talk with liver and adipose tissue[J]. Physiol Rep, 2020, 8(19):14607.
[19] LU H, ELENA B,YU Z, et al. Combined hyperglycemia-and hyperinsulinemia-induced insulin resistance in adipocytes is associated with dual signaling defects mediated by PKC-ζ[J]. Endocrinology, 2018, 159(4):1658-1677.
[20] IGOR O S, JIANG H F, LIU J, et al. Hepatic stellate cell activation: A source for bioactive lipids[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(5):629-642.
[21] ALEXANDRE M, LUC R, MAUD M, et al. Growth differentiation factor-8(GDF8)/myostatin is a predictor of troponin I peak and a marker of clinical severity after acute myocardial infarction[J]. J Clin Med, 2019, 9(1):116.
[22] 陈羽斐, 沈伟, 施海明. 巨噬细胞免疫代谢与动脉粥样硬化的研究进展[J]. 中国动脉硬化杂志, 2020, 28(1):74-80.
[23] 苑莉莉, 罗彬, 王佳贺. 脂蛋白相关磷脂酶A2在老年糖尿病诊治中的研究进展[J].实用老年医学, 2020, 34(10):1011-1014.
[24] BUTCHER J T, MINTZ J D, LARION S, et al. Increased muscle mass protects against hypertension and renal injury in obesity[J]. J Am Heart Assoc, 2018, 7(16):9358.
[25] BARBARA L B, TIMOTHY S W, PATRICIA G C, et al. Postnatal PPARδ activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice[J]. PLoS One, 2010, 5(6):11307.
[26] MANUEL F L, CARLOTA T, VÍCTOR V, et al. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk[J]. Nutrients, 2019, 11(11):2664.
[27] BOGDANOVICH S, KRAG T O, BARTON E R, et al. Functional improvement of dystrophic muscle by myostatin blockade[J]. Nature, 2002, 420(6914):418-421.
[28] 林金榕, 田家齐, 孙亚英, 等. 肌生成抑制素(MSTN)抗体对肩袖撕裂后肌肉退变的治疗效果[J]. 中国运动医学杂志, 2020, 39(11):870-877.
[29] GREEN D J, HOPMAN M, PADILLA J, et al. Vascular adaptation to exercise in humans: role of hemodynamic stimuli[J]. Physiol Rev, 2017, 97(2):495-528.
[30] WAGNER K R, FLECKENSTEIN J L, AMATO A A, et al. Phase I/II trial of MYO-029 in adult subjects with muscular dystrophy[J]. Ann Neurol, 2008, 63(5):561-571.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	. [J]. Practical Geriatrics, 2024, 38(10): 979-982.
[2]	GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song. Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure [J]. Practical Geriatrics, 2024, 38(10): 1025-1029.
[3]	LIU Jin, HUANG Yanqiu, ZHU Yi, ZHUO Lili. Effects of sacubitril valsartan sodium in elderly patients with chronic heart failure [J]. Practical Geriatrics, 2024, 38(10): 1030-1033.
[4]	XU Shouyong, YUAN Yong. Study on feasibility of dual-low-dose CT coronary angiography in elderly patients [J]. Practical Geriatrics, 2024, 38(10): 1054-1058.
[5]	LIU Lin, WU Qing, ZHANG Jing, MAO Fangying, YU Lu, REN Yiting, FANG Ting. Status and influencing factors of symptom perception in elderly patients with heart failure [J]. Practical Geriatrics, 2024, 38(5): 461-437.
[6]	WANG Chao, CHEN Xiaojun. Influence of tropical climate on blood pressure, peripheral blood microRNA-146a and Hcy in elderly patients with essential hypertension from northeast China [J]. Practical Geriatrics, 2024, 38(5): 470-437.
[7]	LIU Qianhui, YAO Zijun, HE Yuli, XU Yunfan, WU Jun. Effects of HbA1c level on cardiac structure and function in elderly patients with type 2 diabetes mellitus and chronic heart failure [J]. Practical Geriatrics, 2024, 38(5): 491-437.
[8]	ZHANG Lili, LI Jing, DING Linfeng, SUN Jingxian, CAI Jingbo. Predictive value of carotid atherosclerosis plaque for ischemic stroke events in patients with nonvalvular atrial fibrillation [J]. Practical Geriatrics, 2024, 38(3): 236-239.
[9]	ZHA Zhimin, LIU Huan, WANG Xiangming, LI Qiushuang, GUO Yan. Effect of cardiac valve calcification on prognosis of elderly patients with coronary heart disease [J]. Practical Geriatrics, 2024, 38(3): 245-250.
[10]	. [J]. Practical Geriatrics, 2024, 38(3): 299-303.
[11]	. [J]. Practical Geriatrics, 2024, 38(3): 308-311.
[12]	CHENG Qing, XU Yan, CHEN Guofei, DENG Xinyue. Correlation of serum angiotensin Ⅱ and nitric oxide levels with cognitive dysfunction in elderly patients with chronic heart failure [J]. Practical Geriatrics, 2024, 38(2): 132-135.
[13]	ZHANG Ying, XIE Ling, YE Jiaqi, QIANG Wenhui, YAN Xiaoyun, JIANG Ying, ZHANG Qing. Correlation between laminin and major adverse cardiovascular events in elderly patients with acute myocardial infarction [J]. Practical Geriatrics, 2024, 38(2): 149-151.
[14]	DUAN Lidan, XI Ling, XU Jianping. Correlation between TyG index and left ventricular diastolic function in elderly hypertensive patients with normal ejection fraction [J]. Practical Geriatrics, 2024, 38(2): 152-156.
[15]	FAN Ting-yong, YUAN Li, YANG Xiao-ling, CHEN Qian. Assessment effect of Caprini scale on venous thromboembolism in elderly patients with diabetes [J]. Practical Geriatrics, 2023, 37(12): 1233-1237.